InvestorsHub Logo
Followers 270
Posts 15407
Boards Moderated 1
Alias Born 03/28/2013

Re: JB3729 post# 69653

Sunday, 07/24/2016 7:05:33 PM

Sunday, July 24, 2016 7:05:33 PM

Post# of 471381
“With Anavex drug candidates targeting the sigma-1 receptor, and with the mechanism of action being further validated, we are even more encouraged to advance our studies with additional neurodegenerative diseases,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The Company is intrigued to realize the direct link to the body’s endocannabinoid system..."


Anavex + cannabinoids + research = POTENTIAL MEDICAL MIRACLES

$AVXL
big smile
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News